Dataset Information

The study protocol for the China Health Big Data (China Biobank) project.

ABSTRACT: Background:Osteoporosis, obesity, and fatty liver are increasingly common chronic diseases that seriously threaten people's health. Low-dose chest computed tomography (LDCT) scan is frequently used for lung cancer screening in health screenings and checkups. Quantitative computed tomography (QCT) enables the accurate measurement of volumetric bone mineral density (vBMD), liver fat content, and abdominal fat area using the existing LDCT data without extra radiation. We initiated a new project, the China Health Big Data (China Biobank), which combines the LDCT scan images from lung cancer screening of participants in health checkup with QCT to investigate the added value of QCT to LDCT, in order to establish the normative reference database and diagnosis criteria for the three aforementioned conditions. Methods:The China Biobank project is a prospective nationwide multicenter cohort study that will combine QCT technology with LDCT scans to measure bone mineral density (BMD), intra-abdominal fat distribution, and liver fat content of the generally healthy checkup participants. Mindways QCT calibration phantom (Mindways Software Inc., Austin, TX, USA) and analysis software QCT PRO v6.0 will be used for all centers. Before data collection begins, the European Spine Phantom (ESP) will be used for quality control analysis at each collaborating center. The inclusion criteria are a healthy checkup participant aged 30-90 years, with LDCT as a part of his/her health checkup protocol. Exclusion criteria are pregnant women or participants with a metal implant in the CT scan area. The LDCT images will be transferred to the Mindways workstation for analysis, and vBMD in the L1 and L2 vertebrae, visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), and liver fat content will be measured. As part of the health checkup, the demographic, anthropometric parameters, blood pressure, and a routine blood laboratory test will be collected. The estimated sample size will be about 30,000. Results:The combination of QCT with LDCT of the chest was validated in this project. The vBMD of spine, visceral fat and liver fat can be measured with a LDCT chest scan. Conclusions:The China Biobank project will assess the added value of QCT to LDCT, and enable accurate evaluation of the prevalence of osteoporosis, obesity, and fatty liver disease in a very large Chinese cohort.

SUBMITTER: Wu Y

PROVIDER: S-EPMC6629571 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

The study protocol for the China Health Big Data (China Biobank) project.

Wu Yan Y Guo Zhe Z Fu Xiaoxia X Wu Jing J Gao Jianbo J Zeng Qiang Q Fu Haihong H Cheng Xiaoguang X

Quantitative imaging in medicine and surgery 20190601 6

<h4>Background</h4>Osteoporosis, obesity, and fatty liver are increasingly common chronic diseases that seriously threaten people's health. Low-dose chest computed tomography (LDCT) scan is frequently used for lung cancer screening in health screenings and checkups. Quantitative computed tomography (QCT) enables the accurate measurement of volumetric bone mineral density (vBMD), liver fat content, and abdominal fat area using the existing LDCT data without extra radiation. We initiated a new pro ...[more]

PMID: 31367563

Similar Datasets

Project description:INTRODUCTION:Data based on electronic health records (EHRs) are rich with individual-level longitudinal measurement information and are becoming an increasingly common data source for clinical risk prediction worldwide. However, few EHR-based cohort studies are available in China. Harnessing EHRs for research requires a full understanding of data linkages, management, and data quality in large data sets, which presents unique analytical opportunities and challenges. The purpose of this study is to provide a framework to establish a uniquely integrated EHR database in China for scientific research. METHODS AND ANALYSIS:The CHinese Electronic health Records Research in Yinzhou (CHERRY) Study will extract individual participant data within the regional health information system of an eastern coastal area of China to establish a longitudinal population-based ambispective cohort study for cardiovascular care and outcomes research. A total of 1 053 565 Chinese adults aged over 18 years were registered in the health information system in 2009, and there were 23 394 deaths from 1 January 2009 to 31 December 2015. The study will include information from multiple epidemiological surveys; EHRs for chronic disease management; and health administrative, clinical, laboratory, drug and electronic medical record (EMR) databases. Follow-up of fatal and non-fatal clinical events is achieved through records linkage to the regional system of disease surveillance, chronic disease management and EMRs (based on diagnostic codes from the International Classification of Diseases, tenth revision). The CHERRY Study will provide a unique platform and serve as a valuable big data resource for cardiovascular risk prediction and population management, for primary and secondary prevention of cardiovascular events in China. ETHICS AND DISSEMINATION:The CHERRY Study was approved by the Peking University Institutional Review Board (IRB00001052-16011) in April 2016. Results of the study will be disseminated through published journal articles, conferences and seminar presentations, and on the study website (http://www.cherry-study.org).

Project description:INTRODUCTION:The holistic management of hearing loss (HL) requires an understanding of factors that predict hearing aid (HA) use and benefit beyond the acoustics of listening environments. Although several predictors have been identified, no study has explored the role of audiological, cognitive, behavioural and physiological data nor has any study collected real-time HA data. This study will collect 'big data', including retrospective HA logging data, prospective clinical data and real-time data via smart HAs, a mobile application and biosensors. The main objective is to enable the validation of the EVOTION platform as a public health policy-making tool for HL. METHODS AND ANALYSIS:This will be a big data international multicentre study consisting of retrospective and prospective data collection. Existing data from approximately 35?000?HA users will be extracted from clinical repositories in the UK and Denmark. For the prospective data collection, 1260?HA candidates will be recruited across four clinics in the UK and Greece. Participants will complete a battery of audiological and other assessments (measures of patient-reported HA benefit, mood, cognition, quality of life). Patients will be offered smart HAs and a mobile phone application and a subset will also be given wearable biosensors, to enable the collection of dynamic real-life HA usage data. Big data analytics will be used to detect correlations between contextualised HA usage and effectiveness, and different factors and comorbidities affecting HL, with a view to informing public health decision-making. ETHICS AND DISSEMINATION:Ethical approval was received from the London South East Research Ethics Committee (17/LO/0789), the Hippokrateion Hospital Ethics Committee (1847) and the Athens Medical Center's Ethics Committee (KM140670). Results will be disseminated through national and international events in Greece and the UK, scientific journals, newsletters, magazines and social media. Target audiences include HA users, clinicians, policy-makers and the general public. TRIAL REGISTRATION NUMBER:NCT03316287; Pre-results.

Project description:IntroductionThe European Environment Agency estimates that 75% of the European population lives in cities. Despite the many advantages of city life, the risks and challenges to health arising from urbanisation need to be addressed in order to tackle the growing burden of disease and health inequalities in cities. This study, Urban environment and health: a cross-sectional multiregional project based on population health surveys in Spain (DAS-EP project), aims to investigate the complex association between the urban environmental exposures (UrbEEs) and health.Methods and analysisDAS-EP is a Spanish multiregional cross-sectional project that combines population health surveys (PHS) and geographical information systems (GIS) allowing to collect rich individual-level data from 17 000 adult citizens participating in the PHS conducted in the autonomous regions of the Basque Country, Andalusia, and the Valencian Community, and the city of Barcelona in the years 2021-2023. This study focuses on the population living in cities or metropolitan areas with more than 100 000 inhabitants. UrbEEs are described by objective estimates at participants' home addresses by GIS, and subjective indicators present in PHS. The health outcomes included in the PHS and selected for this study are self-perceived health (general and mental), prevalence of chronic mental disorders, health-related quality of life, consumption of medication for common mental disorders and sleep quality. We aim to further understand the direct and indirect effects between UrbEEs and health, as well as to estimate the impact at the population level, taking respondents' sociodemographic and socioeconomic characteristics, and lifestyle into consideration.Ethics and disseminationThe study was approved by the regional Research Ethics Committee of the Basque Country (Ethics Committee for Research Involving Medicinal Products in the Basque Country; PI2022138), Andalusia (Biomedical Research Ethics Committee of the Province of Granada; 2078-N-22), Barcelona (CEIC-PSMar; 2022/10667) and the Valencian Community (Ethics Committee for Clinical Research of the Directorate General of Public Health and Center for Advanced Research in Public Health; 20221125/04). The results will be communicated to the general population, health professionals, and institutions through conferences, reports and scientific articles.

Dataset Information

The study protocol for the China Health Big Data (China Biobank) project.

Publications

The study protocol for the China Health Big Data (China Biobank) project.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets